Fulvestrant Alone Versus Fulvestrant and Everolimus Versus Fulvestrant, Everolimus and Anastrozole: A Phase III Randomized Placebo-Controlled Trial in Postmenopausal Patients
Phase of Trial: Phase III
Latest Information Update: 21 Dec 2017
Price : $35 *
At a glance
- Drugs Anastrozole (Primary) ; Everolimus (Primary) ; Fulvestrant (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 14 Dec 2017 Planned End Date changed from 1 May 2018 to 1 May 2022.
- 14 Dec 2017 Planned primary completion date changed from 1 Sep 2017 to 1 May 2022.